J Korean Med Assoc.  2016 Mar;59(3):175-179. 10.5124/jkma.2016.59.3.175.

Chemotherapy for ovarian cancer

• Lim MC
• Park SY

• KMID: 2382721
• DOI: http://doi.org/10.5124/jkma.2016.59.3.175

Abstract

The standard treatment for epithelial ovarian cancer is maximal cytoreductive surgery and adjuvant chemotherapy. Neoadjuvant chemotherapy can be considered as an alternative treatment strategy when unacceptable primary surgery, in terms of gross residual tumor remaining at the end of cytoreduction, is expected or in cases where poor general condition renders extensive cytoreductive surgery unsuitable. Intraperitoneal chemotherapy is ideal for epithelial ovarian cancer because its spread is mainly limited to the peritoneal cavity. Several randomized controlled trials have reported a survival gain with intraperitoneal chemotherapy. However, disadvantages such as port-related complications, abdominal pain, and neurotoxicity hinder its wide use. Hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery has been suggested as an alternative treatment strategy for intraperitoneal chemotherapy. Ongoing clinical trials of hyperthermic intraperitoneal chemotherapy will quantify clinical outcomes in the future, such as the survival benefit in epithelial ovarian cancer.

Keyword

Ovarian neoplasms; Drug therapy; Intraperitoneal chemotherapy; Hyperthermic intraperitoneal chemotherapy

MeSH Terms

Abdominal Pain
Chemotherapy, Adjuvant
Drug Therapy*
Neoplasm, Residual
Ovarian Neoplasms*
Peritoneal Cavity

Reference

1. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, Casado A. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010; 102:982–987.

2. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386:249–257.

3. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group. NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363:943–953.

4. Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment out-comes for ovarian cancer. Onkologie. 2010; 33:324–330.

5. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debul-king surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant che-motherapy (NACT). Gynecol Oncol. 2012; 124:10–14.

6. Lim MC, Park SY. Standardization of cytoreductive surgery is a precondition for clinical trials of ovarian cancer including cytoreductive surgery and/or neoadjuvant chemotherapy. Gynecol Oncol. 2012; 125:510.

7. Choi HJ, Lim MC, Bae J, Cho KS, Jung DC, Kang S, Yoo CW, Seo SS, Park SY. Region-based diagnostic performance of multidetector CT for detecting peritoneal seeding in ovarian cancer patients. Arch Gynecol Obstet. 2011; 283:353–360.

8. Lim MC, Seo SS, Kang S, Kim SK, Kim SH, Yoo CW, Park SY. Intraoperative image-guided surgery for ovarian cancer. Quant Imaging Med Surg. 2012; 2:114–117.

9. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K. Japanese Gynecologic Oncology Group. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary perito-neal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013; 14:1020–1026.

10. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. Gynecologic Onco-logy Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34–43.

11. Gradyaug D. Effective ovarian cancer treatment is underused, study finds. The New York Times. . 2015. 08. 03.

12. Wright AA, Cronin A, Milne DE, Bookman MA, Burger RA, Cohn DE, Cristea MC, Griggs JJ, Keating NL, Levenback CF, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland JC, Weeks JC, O'Malley DM. Use and effectiveness of intra-peritoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015; 33:2841–2847.

13. Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2012; 125:621–624.

14. Lim MC, Kang S, Choi J, Song YJ, Park S, Seo SS, Park SY. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epi-thelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol. 2009; 16:993–1000.

15. Park SY. Intraoperative hyperthermic intraperitoneal che-motherapy with ovarian cancer [Internet]. Bethesda: Clinical-Trials.gov;2014. cited 2016 Feb 27. Available from: https://clinicaltrials.gov/ct2/show/NCT01091636?term=Intraoperative+Hyperthermic+Intraperitoneal+Chemotherapy+With+Ovarian+Cancer.&rank=1.

16. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM. MRC OV05. EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376:1155–1163.

17. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991; 9:389–393.